One institutional experience with imatinib mesylate in the treatment of gastrointestinal stromal tumors

被引：0
|
作者：
Tamas, Karin R.
Papai, Zsuzsa
Vegh, Eva A.
Petranyi, Agota E.
Szucs, Zoltan
Rohanszky, Magda
Aranyi, Zsuzsa
Bodoky, Gyorgy
机构：
[1] St Laslo Hosp, Budapest, Hungary
[2] Natl Med Ctr, Budapest, Hungary
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：164 / 164
页数：1
相关论文
共 50 条
  • [21] Clinical response to imatinib mesylate in recurrent and metastatic gastrointestinal stromal tumors
    Villalobos, R.
    Hernandez, G.
    Martinez-Prieto, M.
    Silva, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
    Tang, Sumin
    Yin, Yuan
    Shen, Chaoyong
    Chen, Jiaju
    Yin, Xiaonan
    Zhang, Bo
    Yao, Yuqin
    Yang, Jinliang
    Chen, Zhixin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2017, 15
  • [23] Necrotizing granulomatous disease in patients receiving imatinib mesylate treatment for gastrointestinal stromal tumors (GIST)
    Brueckl, V
    Agaimy, A.
    Ullrich, E.
    Krieg, S.
    Stegmann, A.
    Mackensen, A.
    Meidenbauer, N.
    ONKOLOGIE, 2011, 34 : 252 - 252
  • [24] A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor
    Ben Ami, Eytan
    Demetri, George D.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 571 - 578
  • [25] Necrotizing granulomatous disease in patients receiving imatinib mesylate treatment for gastrointestinal stromal tumors (GIST)
    Meidenbauer, N.
    Stegmann, A.
    Mackensen, A.
    Agaimy, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] A Decade of Experience with Postoperative Imatinib Mesylate for Gastrointestinal Stromal Tumors: Does the Duration of Treatment Increase Long-term Survival?
    O'Connor, V.
    Deutsch, G. B.
    Arena, E. A.
    Albright, J.
    O'Connor, R. P.
    Sim, M.
    Bilchik, A.
    Ellenhorn, J. D.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : S29 - S30
  • [27] Treatment of gastrointestinal stromal tumor with imatinib mesylate: A retrospective single-center experience in Heidelberg
    Kasper, Bernd
    Kallinowski, Birgit
    Herrmann, Thomas
    Lehnert, Thomas
    Mechtersheimer, Gunhild
    Geer, Thomas
    Ho, Anthony D.
    Egerer, Gerlinde
    DIGESTIVE DISEASES, 2006, 24 (1-2) : 207 - 211
  • [28] Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function
    Bauer, S
    Hagen, V
    Pielken, HJ
    Bojko, P
    Seeber, S
    Schütte, J
    ANTI-CANCER DRUGS, 2002, 13 (08) : 847 - 849
  • [29] Survival benefit of imatinib mesylate on patients with advanced gastrointestinal stromal tumors (GIST)
    Lin, M. T.
    Hu, T. H.
    Lin, J. W.
    Wang, C. C.
    Rau, K. M.
    Changchien, C. S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A44 - A44
  • [30] Immediate action of imatinib mesylate on calcium signaling in gastrointestinal stromal tumors (GIST)
    Berglund, E.
    Lu, M.
    Akcakaya, P.
    Zedenius, J.
    Nilsson, I.
    Ahlen, J.
    Lui, W.
    Larsson, C.
    Branstrom, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345